A Phase 1, Open-label, Randomized, Two-Part Study to Assess the Safety and Pharmacokinetics of Tablet and Capsule Formulations of HU6 in Healthy Subjects.
Latest Information Update: 23 Apr 2025
At a glance
- Drugs HU 6 (Primary) ; HU 6
- Indications Heart failure; Hypertriglyceridaemia; Non-alcoholic steatohepatitis; Obesity; Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Rivus Pharmaceuticals
Most Recent Events
- 18 Apr 2025 Status changed from recruiting to completed.
- 28 Aug 2024 Status changed from not yet recruiting to recruiting.
- 12 Jul 2024 New trial record